Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 March 2004Website:
http://halozyme.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
HALO Latest News
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024.
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Helen Torley - President, Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Tram Bui - Vice President of Investor Relations, Corporate Communications Conference Call Participants Brendan Smith - TD Cowan Mike DiFiore - Evercore ISI Jason Butler - Citizens JMP Corinne Jenkins - Goldman Sachs Mitchell Kapoor - H.C. Wainwright Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Operator Good afternoon.
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago.
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 1 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2024, and provided an update on its recent corporate activities and outlook. "Our robust third quarter financial results highlight the strong execution and accelerating momentum we have across our business and exceeded expectations with total revenue growth of 34% and adjusted EBITDA growth of 60%.
SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
What type of business is Halozyme Therapeutics?
Halozyme Therapeutics Inc. is a company that specializes in a technological platform for biopharmaceuticals, offering innovative solutions to improve patient treatment outcomes. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Currently, Hylenex is the only FDA-approved product from Halozyme Therapeutics on the market. It is the only commercially available patented product, and the company also has three market partner products. All approved products are based on rHuPH20. The patented enzyme rHUPH20 is used to facilitate the delivery of injectable drugs and fluids.
What sector is Halozyme Therapeutics in?
Halozyme Therapeutics is in the Healthcare sector
What industry is Halozyme Therapeutics in?
Halozyme Therapeutics is in the Biotechnology industry
What country is Halozyme Therapeutics from?
Halozyme Therapeutics is headquartered in United States
When did Halozyme Therapeutics go public?
Halozyme Therapeutics initial public offering (IPO) was on 16 March 2004
What is Halozyme Therapeutics website?
https://halozyme.com
Is Halozyme Therapeutics in the S&P 500?
No, Halozyme Therapeutics is not included in the S&P 500 index
Is Halozyme Therapeutics in the NASDAQ 100?
No, Halozyme Therapeutics is not included in the NASDAQ 100 index
Is Halozyme Therapeutics in the Dow Jones?
No, Halozyme Therapeutics is not included in the Dow Jones index
When was Halozyme Therapeutics the previous earnings report?
No data
When does Halozyme Therapeutics earnings report?
The next expected earnings date for Halozyme Therapeutics is 06 November 2024